Skip to content
MARKETS / NASDAQ / STTK
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Shattuck Labs, Inc. STTK

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.0M
▼ 82.5% YoY
$-48.8M
$-40.0M
In brief

What this company does

Our lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to DR3 and inhibit its interaction with its ligand, TL1A. In addition to SL-325 and SL-425 (a half-life extended version of SL-325), we are developing bispecific antibodies which co-target DR3 and other clinically validated targets in immune mediated and inflammatory diseases. We are currently conducting a single ascending dose (“SAD”) and multiple ascending dose (“MAD”) Phase 1 clinical trial evaluating SL-325 in healthy volunteers. We were incorporated in Delaware in May 2016.

Written from the business description in Shattuck Labs, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth
USD 1.0M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.0 · Net income -48.8
20M-40M-80M2019202020212022202320242025
Compound annual growth
+15.3%
−36.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −36.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−4881 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -5150.8% · Net -4880.9%
-5000%-10000%-15000%2019202020212022202320242025
ROE
FY2025 · ROE -60.3%
-20%-40%-60%2019202020212022202320242025

Each USD of equity lost 60 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -40.0
-40M-80M2019202020212022202320242025

Total assetsUSD 91.0M
EquityUSD 82.4M
CashUSD 54.2M
Current ratio11.70×

Equity funds 91% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B−0.0−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.1−0.1−0.1−0.1−0.0−0.0
EPS, diluted $−0.70−1.49−2.05−2.41−1.07−2.36−3.17
Dividend / sh $·······
Payout %·······
ROE %−60.3−67.2−54.4−45.5−15.5−26.6·
Shares out B0.060.050.050.040.040.040.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 48 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image